14 completed, 2 terminated, 2 unknown, 1 active not recruiting. 20 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 14, Terminated 2, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Filariasis: new trials by email Literature Review of Filariasis trials Research Report on Filariasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 255 | 2021-01-16 | 2021-09-20 |
| Safety and Efficacy of IDA for Onchocerciasis IVM w/ ALB, Single dose of IDA, Three daily doses of IDA - Onchocerciasis | Phase 2 | Completed | Washington University School of Medicine | 154 | 2019-12-06 | 2024-06-04 |
| Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Imatinib Mesylate, Placebo - Loiasis | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2019-09-16 | 2022-06-07 |
| PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Azithromycin, Albendazole, Ivermectin - Lymphatic Filariasis, Yaws | Phase 2 | Completed | Lihir Medical Centre | 42 | 2018-09-01 | 2019-02-28 |
| Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Ivermectin, Albendazole - Malaria, Lymphatic Filariasis | Phase 2 / Phase 3 | Completed | Colorado State University | 2712 | 2015-06-01 | 2019-01-04 |
| Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Doxycycline - Mansonella Perstans Infection, Buruli Ulcer | Phase 2 | Completed | Kwame Nkrumah University of Science and Technology | 200 | 2014-10-01 | 2017-03-23 |
| Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Diethylcarbamazine, Albendazole, Ivermectin - Lymphatic Filariasis | Phase 2 | Completed | University Hospitals Cleveland Medical Center | 182 | 2014-05-01 | 2018-10-09 |
| Pediatric Pharmacokinetics And Safety Study Of Moxidectin moxidectin - Onchocerciasis | Phase 2 | Withdrawn | Pfizer | 2011-04-01 | 2012-03-29 | |
| Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Reslizumab, Diethylcarbamazine, Placebo - Loiasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 31 | 2010-04-01 | 2022-01-27 |
| Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Albendazole, Diethylcarbamazine - Lymphatic Filariasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2007-07-01 | 2015-08-31 |
| Effect of Albendazole Dose on Clearance of Filarial Worms DEC/Albendazole - Lymphatic Filariasis, Wuchereria Bancrofti Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1000 | 2006-09-09 | 2017-07-02 |
| Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection 2 mg moxidectin, ivermectin 150 mcg/kg, 4 mg moxidectin - Onchocerciasis | Phase 2 | Completed | Medicines Development for Global Health | 172 | 2006-09-06 | 2022-12-15 |
| Effect of Albendazole Dose on Clearance of Filarial Worms Albendazole, Ivermectin - Lymphatic Filariasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1000 | 2006-02-22 | 2017-07-02 |
| Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Doxycycline - Mansonella Perstans Infection, Mp Microfilaremia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1500 | 2004-12-06 | 2017-07-02 |
| Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Rifampin, Azithromycin - Onchocerciasis | Phase 2 | Completed | Centers for Disease Control and Prevention | 80 | 2003-07-01 | 2024-08-15 |
Onchocerciasis (8) · Onchocerciasis, Ocular (7) · Elephantiasis, Filarial (6) · Loiasis (5) · Mansonelliasis (2) · Buruli Ulcer (1) · Coinfection (1) · Dipetalonema Infections (1) · Enterobiasis (1) · Helminthiasis (1) · Malaria (1) · Neglected Diseases (1) · Nematode Infections (1) · Parasitic Diseases (1)
Infections (20) · Secernentea Infections (20) · Spirurida Infections (20) · Helminthiasis (19) · Nematode Infections (19) · Parasitic Diseases (19) · Vector Borne Diseases (13) · Skin and Connective Tissue Diseases (10) · Skin Diseases (9) · Skin Diseases, Infectious (8) · Eye Diseases (7) · Eye Infections (7) · Eye Infections, Parasitic (7) · Skin Diseases, Parasitic (7)
Ivermectin (8) · Albendazole (7) · Diethylcarbamazine (5) · moxidectin (4) · Albumins (2) · Azithromycin (2) · Doxycycline (2) · Levamisole (2) · Bay 44-4400 (1) · Imatinib Mesylate (1) · Intravital Microscopy (1) · Rifampin (1) · Tablets (1) · emodepside (1) · reslizumab (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Washington University School of Medicine (2) · AbbVie (1) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Centers for Disease Control and Prevention (1) · Colorado State University (1) · Drugs for Neglected Diseases (1) · Kwame Nkrumah University of Science and Technology (1) · Lihir Medical Centre (1) · Medicines Development for Global Health (1) · Pfizer (1) · University Hospitals Cleveland Medical Center (1)
Ghana (4) · United States (3) · Cameroon (2) · Democratic Republic of the Congo (2) · India (2) · Papua New Guinea (2) · Republic of the Congo (2) · Burkina Faso (1) · Guatemala (1) · Liberia (1) · Mali (1)
Gary Weil, MD (2) · Alexander Y Debrah, PhD (1) · Amy D Klion, M.D. (1) · Brian D. Foy, PhD (1) · Christopher King, MD, PhD (1) · Elise M O'Connell, M.D. (1) · Ellis Owusu Dabo, MBChB, PhD (1) · Josef Amann, MD, MPH (1) · Nicholas Opoku, MB, CHB, MSC (1) · Nicholas Opoku, MD (1) · Patrick Kpanyen, PhD (1) · Peter Fischer, PhD (1)
PMID 19812401, PMID 24968000, PMID 26486704, PMID 28061905, PMID 30403937, PMID 30878222, PMID 32818264, PMID 34651190, PMID 37205721, PMID 37262040, PMID 38966851, PMID 40615414, PMID 42848323